VEGF gene mRNA expression in patients with coronary artery disease

To assess the expression of vascular endothelium growth factor (VEGF) mRNA in unstimulated peripheral blood mononuclear cells of patients with and without coronary artery disease (CAD). We also studied whether the functional VEGF −2578*C/A polymorphism may influence the level of VEGF mRNA expression in individuals undergoing coronary angiography because chest pain. We assessed 50 consecutive patients with angiographically confirmed CAD (CAD+). Also, 50 consecutive individuals with normal coronary studies were included in the study for comparison. VEGF mRNA expression was examined using quantitative real-time PCR and genotyping for VEGF −2578*C/A was performed using ARMS–PCR technique. VEGF mRNA expression was significantly decreased in CAD+ patients when compared to CAD− individuals (p = 0.01). The frequency of VEGF −2578 allele C and genotype CC was increased in CAD+ patients. In this regard, homozygosity for the CC genotype was more commonly observed in CAD+ (30 %) than in those without CAD disease (18 %). However, the difference was slightly out of the range of significance (p = 0.1). In addition, a trend for reduction in the expression of VEGF mRNA was observed when patients carrying the VEGF −2578*AA genotype were compared with those VEGF −2578*AC heterozygous or those homozygous for the VEGF −2578*CC genotype. VEGF gene expression is decreased in individuals with CAD+ disease. The VEGF −2578*C/A polymorphism may influences the expression of VEGF.